Join HSANZ
HSANZ Member, Professor John Seymour, Director of Clinical Haematology at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, has been named as among the most influential in the world in the annual Highly Cited Researchers 2020 list
The list identifies scientists who have published papers ranking in the top 1% by citations by peers in their field over the past ten years. Among the 6,400 Highly Cited Researchers across 21 fields of the sciences there are 482 named in the clinical sciences section and 199 in immunology research.
See this article in the limbic for full story
HSANZ is pleased to be invited again to partner the American Society of Hematology for the Highlights of ASH series which will be taking place virtually in March 2021. All Members of HSANZ will be entitled to a discounted registration.
ASH is excited to share additional information in the coming weeks, but the regional meetings originally scheduled to take place in North America (January), the Mediterranean (February), Asia-Pacific (March), and Latin America (April) will be offered as as a collective virtual experience in March 2021. More information about the program and registration will be available in early 2021.
Meanwhile, here is the 2021 Highlights of ASH website. As soon as we know more, we will post it here.
LF has put together a page on our PhD Scholarship recipients. We thought you might like to see it too.
Click here
HSANZ were pleased to be a signatory to the National Strategic Action Plan for Blood Cancer coordinated by the Leukaemia Foundation.
Blood cancers are one of the most commonly diagnosed cancers in Australia today and one of the biggest causes of cancer death.
The National Strategic Action Plan for Blood Cancer is a blueprint to coordinate and accelerate national efforts to improve survival and quality of life for people diagnosed with blood cancer and to support their carers and families.
It identifies four major priorities:
The National Action Plan was commissioned by the Australian Government and launched by the health Minister in September 2020.
Announcement of Scholarship and Award recipients
At the recent HSANZ Education Day and AGM, President Leanne Berkahn and Vice President Steven Lane announced a number of awards.
Congratulations firstly to three new Life Members of HSANZ:
Linda Campbell from Melbourne
Kathryn Crosier from Nelson, New Zealand and
Paul Vincent from Sydney
Congratulations to Scholarship and Fellowship awardees
Leukaemia Foundation PhD Scholarship recipients:
Basit Salik - QIMR Berghofer Medical Research Institute
Julian Grabek - QIMR Berghofer Medical Research Institute
HSANZ New Investigator Clinical Fellowship
Katherine Creeper
Allison Barraclough
The Society wishes to thank Janssen for their contribution to these scholarships
Albert Baikie Medal and award
Danielle Oh
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant.
In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation.
The final seminar of the 2020 CBTCT webinar series features Professor David Curtis reviewing the significance and potential management approaches to minimal residual disease in the peri-allogeneic blood transplant setting, followed by Professor David Ritchie highlighting the importance of the cellular therapies laboratory with the emergence of commercially available chimeric antigen receptor (CAR) T cell therapies.
Speakers:
Professor David Curtis – The Alfred Hospital and Monash University
Professor David Ritchie – Royal Melbourne Hospital and the University of Melbourne
When: Monday 26 October 2020, 12pm AEDT
Link to webinar:
Link to CBTCT website for all webinar recordings:
ALLG October Virtual Scientific Meeting
12 - 16 October 2020
This is a fully packed five-day event for the Haematology Community – NOT your traditional ‘ALLG clinical trials’ meeting.
The sessions are diverse with updates in the following streams: Clinical Practice, How to Treat, Improving Practice and Process in research flow, Educational, Training, Research and Technology updates.
Speakers are local key leaders, International clinicians, and medical and scientific leaders from industry.
The SAC are leading x8 disease specific plenary sessions - by Peter Mollee, Jake Shortt, Nada Hamad, Eliza Hawkes, Tara Cochrane, David Ross, David Yeung, Zoe McQuilten, Stephen Mulligan and Andrew Wei.
If you are involved in the trial program the Working Party Leaders are conducting smaller research discussion meetings – check your meeting rosters!
In addition, sessions the membership has indicated they would like to hear more about
The associate member event is a half day educational session with key members speaking and will be very high-quality education. Andrew Spencer, IngSoo Tiong, Chun Fong, and Naranie Shanmuganathan.
The half day clinical trial operations update for associate members will be an update on key clinical trial processes.
Next week's sessions includes:
HSANZ have a half day Education day on Tuesday 13 October, with the delivery of the Baikie Symposium and the Pitney Fellow address led by HSANZ President Leanne Berkahn and Vice President Steven Lane
HSANZ has conducted a process to call for abstracts and successful abstracts will be presented.
Support your colleagues and come along to this important event. This is a big deal in the professional haematologist's career, so join-in and cheer them on!
Our opening session Monday 8am – 10am features Peter Mollee, Jake Shortt and Tracey Gerber.
We have Katie Allen MP as a guest speaker and we also have John Seymour and Carrie Hillyard presenting as the National Blood Cancer Taskforce Co-Chairs.
International speakers!
This program includes a broad range of expert international presenters from all over the world. Some have provided recorded presentations but many are attending live …don’t’ miss this opportunity for engagement!
Welcome to the Australia & New Zealand haematology community – Ajai Chari, Peter Borchmann, Gordon Cook, David Kurtz, and Konstanz Dohner
To register now – please contact Lucy Chesterton
Click here for the program
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The fifth webinar in this series features two excellent speakers, with Dr Kate Markey highlighting the emerging significance of the microbiome in influencing outcomes following blood and marrow transplantation, followed by Elissa Atkins who will review the practical aspects of the regulatory requirements for the monitoring of recipients of immune effector cell therapy products.
Dr Kate Markey – Memorial Sloan Kettering Cancer Centre / Weill Cornell Medical College
Elissa Atkins – Westmead Hospital / Westmead Institute for Medical Research
When: Thursday 1 October 2020, 8am AEST
PDF flyer
Dear Colleagues
As you are aware, on 13 March 2020 the Australian Government listed a range of temporary items for specialist specific telehealth services (video and/or phone attendances) in response to the COVID-19 pandemic. Based on stakeholder advice, over 80 specialist specific items were listed in response to the COVID-19 pandemic. These temporary items were due to cease on 30 September 2020.
The Government has agreed to extend the COVID-19 specialist telehealth items in their current form, from 30 September 2020 to 31 March 2021, this extension period is based on advice from the Australian Health Protection Principal Committee (AHPPC). Further information about the extension is available online at: www.pm.gov.au/media/24-billion-health-plan-fight-covid-19
The Department will continue to monitor the impacts of COVID-19, and should the AHPPC recommend a further extension of the current items beyond 31 March 2021, this matter will be brought back to Government for consideration.
If you have any questions about the extension please email
Mary Warner
Director
Medical Specialist Services Section
MBS Policy & Specialist Services Branch | Medical Benefits Division
Australian Government Department of Health
MDP 959, GPO Box 9848, Canberra ACT 2601
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The fourth webinar of this series addresses developments in the field of cellular therapy in the management of two common post-allogeneic bone marrow transplant complications. Professor David Gottlieb will highlight the role of cell therapies in the treatment of opportunistic infections in the post-transplant period, while Dr Siok Tey will review novel cellular therapies for the treatment of graft vs host disease
Professor David Gottlieb – Westmead Hospital / University of Sydney
Dr Siok Tey - Royal Brisbane and Womens Hospital / QIMR Berghofer Medical Research Institute
When: Thursday 3 September 2020, 8am AEST
Link to webinar
Link to CBTCT website for all webinar recordings
For more information
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.
Privacy Policy
